A.T. Development Switzerland

A.T. Development SA is a Swiss-based subsidiary of Antares Pharma (now part of Halozyme Therapeutics) that specializes in the design and development of advanced drug delivery systems. The company focuses on self-injection technologies, including pressure-assisted auto-injectors and multi-dose pen injectors, which are utilized for various therapeutic applications such as hormone replacement and autoimmune diseases. A.T. Development provides engineering and technical expertise to support the parent company's portfolio of proprietary and partnered injectable products. Its facilities in Switzerland serve as a key hub for the research and development of innovative delivery platforms. The company's technology is integrated into several FDA-approved products, including Xyosted and Otrexup. Through its parent company, A.T. Development collaborates with major pharmaceutical partners to provide customized delivery solutions for complex molecules.